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Impact of findings on practice 
o Community pharmacy teams should be educated to give appropriate advice to 
patients reporting potential alarm symptoms; 
o Community pharmacies should have robust referral procedures for patients 
presenting with alarm symptoms; and, 
o Referral pathways for cancer diagnosis, which include a role for community 
pharmacy teams could be the subject of further research.   
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Introduction 
Cancers are a major cause of death worldwide, accounting for over 8 million deaths per 
annum.1 These figures are expected to increase: the World Health Organisation (WHO) 
estimates that, globally, the burden from cancer has more than doubled in the last three 
decades2 with, due to the aging population, a projected increase of 50% in new cancer cases 
annually by 2020.3 In the UK, incidence rates have increased by more than a third in a 
similar time period, with more than 330,000 people diagnosed annually.4 One factor that 
can impact on patient survival is the time taken to reach a cancer diagnosis and implement 
treatment. Currently, in England, late diagnoses for breast, lung and colorectal cancer are 
believed to contribute toward increased mortality rates compared to other European 
countries.5,6  
 
The UK National Institute for Health and Clinical Excellence (NICE) has introduced referral 
guidelines for suspected cancers by primary healthcare professionals with a view to 
improving survival rates.7 The guidelines explain how and when patients presenting with 
symptoms suggestive of a malignancy should be referred to a specialist. These symptoms – 
the so-called alarm symptoms – include haematuria, haemoptysis, dysphagia and rectal 
bleeding and are indicative of cancer in patients presenting to General Practitioners (GPs) 
for routine appointments.8,9 Since the introduction of these guidelines, there is evidence 
that diagnostic delays for some cancers have reduced.9 Despite this and given that the 
projected numbers of cancer diagnoses are set to increase, initiatives to promote the early 
detection of cancer remain a priority. Indeed, particular challenges in the UK relate to 
cancer-related health inequalities.10 That is, incidence rates of certain cancers are higher, 
and prognoses are poorer, for patients living in deprived areas, compared to more affluent 
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ones.  For example, in Scotland the incidence of oesophageal cancer is 74% higher in 
deprived areas, compared to the least deprived.11 Often, in deprived areas, healthcare 
access – a well-established social determinant of health – is lacking and is not sufficient to 
meet the needs of the population.12 
 
One healthcare provider that may have a role in the early detection of cancer is the 
community pharmacist. This has been acknowledged by the UK Department of Health 
(DoH), through the ‘Be Clear on Cancer’ campaign,13 which used pharmacies to inform 
patients about the importance of seeing a GP, should they have an alarm symptom.  Other 
smaller studies have investigated the potential for pharmacies to be involved in referral 
pathways for lung cancer and bowel cancer: both demonstrated that patients present at the 
pharmacy with symptoms indicative of each disease.14,15 Estimates vary with regard to the 
reach of the community pharmacy network, but some sources suggest over 90% of the 
population makes at least one visit per year.16,17  Evidence also suggests patients in the most 
deprived areas have the greatest access to pharmacies – the Positive Pharmacy Care Law18 – 
irrespective of urbanity and that a range of patients – of varying age, gender and social class 
– visit pharmacies every month to collect prescriptions, purchase over-the-counter (OTC) 
medicine and obtain healthcare advice.19 Community pharmacies, therefore, appear to be 
conveniently placed to deliver public health initiatives related to the early detection of 
cancer.  One particular challenge around this proposal is that it is currently unknown what, if 
any, patients with alarm symptoms suggestive of cancer present at pharmacies.    
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Aim of the study 
This study aimed to assess the frequency and mean of patient reported alarm symptoms 
across a representative range of community pharmacies in the North of the United 
Kingdom. We also aimed to explore the relationship between deprivation index of the 
pharmacies and average frequency of presentation per pharmacy per deprivation tertile. 
The study is the first to explore the frequency of alarm symptoms presenting at community 
pharmacies. 
 
Ethical Approval 
The study team was advised that ethical approval was not required, as the work was 
registered with each associated NHS Area Team as a clinical audit, which forms part of the 
requirements of the community pharmacy contractual framework.  All patients included in 
the analysis gave their informed consent to take part in the study.   
 
Methods 
This was a prospective study conducted across 33 community pharmacies located 
throughout Northern England from September 2013 to February 2014.  All of the 
pharmacies were part of the same independent group and offered a range of services 
commissioned under the NHS Community Pharmacy Contractual Framework for England,20 
including the sale of over-the-counter medication and the provision of related advice. 
 
To ensure there was consistency between each pharmacy around knowledge of alarm 
symptoms,7 all staff were provided with education and training lasting around 1 hour; this 
was administered by the superintendent pharmacist for the group and each individual 
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pharmacist provided further training to staff within each pharmacy.  The core of the training 
focused on knowledge of alarm symptoms, but also considered communication skills, 
including how to question patients sensitively without causing unnecessary concern.  During 
the study period, each pharmacy was provided with a list of criteria related as to what 
constitutes an alarm symptom to ensure parity in data collection (adapted from NICE 
guidance7).  This information was periodically reinforced during the study period. The alarm 
symptoms that were recorded were: 
 persistent cough lasting longer than 3 weeks; 
 unexplained dyspepsia lasting longer than 3 weeks;  
 haematuria; 
 persistent diarrhoea or melaena; 
 persistent emesis or haematemesis; 
 rectal bleeding; 
 dysphagia; 
 unexplained weight loss, and  
 lump or mass in the breast. 
 
Patients seeking general advice or specific guidance for minor ailments or those requesting 
to purchase a medicine possibly related to an alarm symptom were questioned using the 
WWHAM question framework.21 For each patient presenting with alarm symptoms the 
following data were recorded: alarm symptom(s) exhibited, gender, ethnicity, and the date 
and time presented. All patients presenting were given appropriate advice and verbally 
referred to their GP by the pharmacist for further investigation; patients were not followed 
up once referred.  
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The location of each pharmacy was mapped to the IMD 2010 deprivation index.22  From this, 
a deprivation tertile for each pharmacy location was calculated. The term ‘deprivation 
tertile’ is used to group the population into three ordinal categories according to a particular 
level of deprivation. Thus, the least deprived tertile (1) equates to the least deprived 33.3% 
within a population, while the most deprived tertile (3) represents the 33.3% of a 
population living in the most deprived circumstances. In addition to deprivation calculations 
the location of each pharmacy was also classified according to the Rural and Urban Area 
Definition for Lower Layer Super Output Areas (LSOA), the pharmacies in this sample were 
all subsequently classified as being either within urban (population of area > 10,000 people) 
or town and fringe areas (part of a settlement where populations <10,000 people).23  
 
Means, standard deviations, or percentages for outcomes were calculated, as appropriate 
using Microsoft Excel and IBM SPSS.  The data were analysed using a Kruskal-Wallis test in 
order to determine whether there were any statistically significant associations between 
average frequency of alarm symptoms presented per pharmacy and the deprivation tertile. 
 
Data was reported on a monthly basis from each pharmacy and results were collected 
consistently throughout the study period.  
 
Results 
During the study period, the total number of people who presented with alarm symptoms at 
the pharmacies was 642; more female (n=378, 58.9%) patients presented than males 
(n=264, 41.1%).  The majority of those presenting with alarm symptoms were white (n=587, 
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91.4%).  Less than 10% were from ethnic minorities, which is comparable to the percentage 
of ethnic minorities residing in the North of England.24 Presenting ethnic minority groups 
included mixed/multiple ethnic groups (n=24, 3.7%) and Asian/British Asian (n=20, 3.1%).  A 
total of 642 alarm symptoms were observed, no patient reported more than one alarm 
symptom.  The frequency of presentation for each alarm symptom is shown in Table 1.  
 
Table 1. Frequency of alarm symptoms presented during the study period. 
 
Alarm symptom Frequency of presentation 
Persistent cough lasting longer than 3 weeks 296 (46.10%) 
Haematuria 49 (7.63%) 
Persistent diarrhoea or melaena 59 (9.19%) 
Unexplained dyspepsia lasting longer than 3 
weeks 
108 (16.82%) 
Lump or mass in the breast 16 (2.49%) 
Rectal bleeding 29 (4.51%) 
Dysphagia 28 (4.36%) 
Persistent emesis or haematemesis 32 (4.98%) 
Unexplained weight loss 25 (3.89%) 
Total 642 (100%) 
 
When each pharmacy was stratified according to deprivation tertile, twenty-one were 
located in high areas of deprivation (of which 18 were urban and 3 were town and fringe), 
nine in medium areas of deprivation (of which 7 were urban and 2 were town and fringe) 
and three in low areas of deprivation (of which 3 were urban).  For pharmacies in areas of 
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high deprivation, the mean number of alarm symptoms reported over the six month period 
was 20.67 (SD=22.7), for medium areas of deprivation the mean was 17.44 (SD=5.0) and, for 
low areas of deprivation, the mean was 17.0 (SD=13.1). Table 2 shows the mean number of 
alarm symptoms presented per pharmacy per tertile of deprivation alongside the Kruskal-
Wallis analysis for each alarm symptom.  Kruskal-Wallis was used owing to the small sample 
size and the data not being normally distributed. There were no statistically significant 
relationshsips between average frequency of presentation of alarm symptoms and 
deprivation tertile. 
 
Table 2. Mean and standard deviation of the number of alarm symptoms presented per 
pharmacy by deprivation tertile over the 6 month study period (with 1 being the least 
deprived and 3 being the most deprived), including Kruskal-Wallis analysis. 
 
Alarm Symptom Deprivation 
Tertile (IMD) 1 
(n=3) 
Deprivation 
Tertile (IMD) 2 
(n=9)  
Deprivation 
Tertile (IMD) 3 
(n=21)  
Kruskal Wallis 
H statistic  (p-
value) 
Persistent cough 
lasting longer 
than 3 weeks 
8.33 
(SD 7.02) 
6.78 
(SD 2.77) 
10.00 
(SD 13.20) 
0.463 
(0.793) 
Haematuria 1.33 
(SD 0.58) 
1.22 
(SD 1.72) 
1.62 
(SD 3.04) 
0.865 
(0.649) 
Persistent 
diarrhoea or 
melaena 
1.00 
(SD 1.73) 
2.11 
(SD 3.44) 
1.76 
(SD 2.34) 
0.423 
(0.809) 
Unexplained 
dyspepsia for 
longer than 3 
weeks 
3.00 
(SD 2.00) 
3.44 
(SD 3.43) 
3.24 
(SD 4.55) 
0.867 
(0.648) 
Lump or mass in 
the breast 
0.33 
(SD 0.58) 
0.67 
(SD 0.87) 
0.43 
(SD 0.93) 
1.002 
(0.606) 
Rectal bleeding 0  0.44 
(SD 0.73) 
1.19 
(SD 1.66) 
3.028 
(0.220) 
Dysphagia 3.00 
(SD 5.20) 
0.78 
(SD 0.83) 
0.57 
(SD 1.43) 
2.329 
(0.312) 
Persistent emesis 
or haematemesis 
0  
 
0.78 
(SD 1.09) 
1.19 
(SD 3.30) 
1.916 
(0.384) 
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Unexplained 
weight loss 
0  1.22 
(SD 1.30) 
0.67 
(SD 1.20) 
4.396 
(0.111) 
 Mean all 
symptoms 
17.00 
(SD 13.11) 
17.44 
(SD 4.98) 
20.67 
(SD 22.68) 
2.025 
(0.363) 
 
 
 
 
 
Discussion 
This is the first study to assess the type and frequency of alarm symptoms presenting at 
community pharmacies over a wide geographical area, ranging from deprived to affluent 
neighbourhoods.  
 
Our data show that patients with a range of alarm symptoms present at community 
pharmacies looking for either healthcare advice or to purchase over-the-counter medication 
to alleviate their symptoms. There was an observation that, on average, more alarm 
symptoms were presented at community pharmacies located in areas of high deprivation, 
compared to those in middle and low areas, although this was not statisitically significant.  
Irrespective of this, the results demonstrate that patients use community pharmacies across 
all deprivation tertiles for advice, and present a range of alarm symptoms, which could be 
indicative of malignant disease.  Considering the specific challenges around cancer-related 
inequalities and that access to healthcare is a well established social determinant of health, 
our results demonstrate that community pharmacy networks could have a role in managing 
these patients by highlighting potential alarm symptoms.  This is of particular importance 
when the reach of the community pharmacy network is considered.18  Some studies have 
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already explored the possibility of using community pharmacies for the early detection of 
lung cancer14 and bowel cancer.15  These studies were, however, conducted over limited 
time periods and only explored one specific alarm symptom.  Our work builds on these 
findings and shows that, over a six month period, a range of alarm symptoms associated 
with different cancers were presented at community pharmacies over a wide geographical 
area, ranging from deprived to affluent neighbourhoods.  In terms of the wider literature 
related to early cancer detection, there have been several initiatives undertaken in a 
community pharmacy setting, which have either focused upon cancer screening or raising 
awareness of cancer prevention.  For example, Potter and colleagues showed that 
community pharmacists can improve the screening rates for colorectal cancer by providing 
patients with home screening tests.25 While Mayer and colleagues found that when 
community pharmacists were given an educational intervention around skin cancer, the 
level of counselling related to skin cancer prevention offered to patients significantly 
increased.26  Recently, Purwani and colleagues, through the Community Pharmacies 
Referrals Project (CoPhaR), examined direct referral pathways to secondary care for patients 
with potential respiratory disease, including lung cancer.27  Of note, this study followed 60 
referrals made from community pharmacy, 55 of which were considered by secondary care 
to be appropriate. Whilst these studies demonstrate there is scope for community 
pharmacists to improve cancer detection, there has, to date, been no published work 
undertaken to explore whether such pathways can improve survival outcomes for patients 
with cancer.  
 
There is evidence from the literature that patients who have advanced symptoms of disease 
present with alarm symptoms at a range of healthcare providers.9,28  Our study shows that 
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patients with a wide range of alarm symptoms present at community pharmacies and 
therefore there are opportunities to identify possible malignancy within that group of 
patients. At present, in the UK, a normal referral pathway for a patient presenting at a 
community pharmacy with an alarm symptom is for the pharmacist to refer to a GP, who 
would then, if they felt it was appropriate according to NICE,7 make a referral to a specialist; 
the referral should usually be within 2 weeks of the GP seeing the patient.  This process is 
informal and is subject to delay; indeed, it is known that many patients, especially those 
from lower socio-economic groups, delay contacting their GP because of fear of time 
wasting or because they are too busy to make an appointment.29  Thus, and given that many 
cancers are diagnosed at an advanced stage when curative treatment is not possible, 
optimising the referral pathway may impact on the time taken to reach a diagnosis and 
contribute to improved patient outcomes.  
 
As nearly half of the patients who presented at a pharmacy had a persistent cough lasting 
longer than 3 weeks, a chest radiograph could be used to help determine if they had lung 
cancer (although diagnosis is based on cytology), which is, according to NICE, recommended 
in a patient experiencing these symptoms.7 This is significant, as approximately 90% of 
patients with lung cancer are symptomatic at the time of diagnosis with the majority of 
patients having a cough.30 Our findings are timely as, in England, survival rates of lung 
cancer are worse in comparison to other European countries.  Furthermore, it has been 
estimated that if survival rates for lung cancer mirrored the best performing European 
countries, 1300 deaths could be avoided in England each year.31  Indeed, one of the 
challenges around lung cancer survival is that around 70% of cases are diagnosed at an 
advanced stage, with 39% of them presenting as an emergency.28 Due to these challenges 
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there should be an emphasis on developing strategies to help promote the earlier detection 
of cancer.  One element of this, given that our data show patients present at pharmacies 
with alarm symptoms, would be to explore the referral procedures between pharmacies 
and GPs.  In this regard, a qualitative study exploring the acceptability and challenges of 
opening up referral pathways from the perspective of patients, physicians and community 
pharmacists would therefore be valuable. 
In terms of study limitations, we acknowledge that just because a patient has an alarm 
symptom does not necessarily mean they have cancer.  Indeed, alarm symptoms can also be 
associated with undiagnosed long-term conditions (e.g. a persistent cough can be a sign of 
Chronic Obstructive Pulmonary Disease).  As patients were not followed up after the initial 
presentation, it is not clear what proportion, if any, had cancer – or if cancer was confirmed 
how it was staged in comparison to patients initially presenting at a GP. We also 
acknowledge that while we assigned each pharmacy a deprivation tertile, we did not 
consider deprivation tertile of the presenting patient.  In the majority of cases, we assume 
patients visit their local pharmacies, but it is possible that patients from one deprivation 
tertile use a pharmacy from another deprivation tertile. Equally, our results are partialy 
confounded in that more of the pharmacies in the sample were located in poorer areas 
increasing the likelihood of higher numbers of presentations in the more deprived areas. A 
larger study, specifically powered to detect differences in frequency of presentation 
between pharmacies located in different deprivation tertiles would be of benefit. 
 
 
 
Conclusions 
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Patients with alarm symptoms frequently present at community pharmacies over a wide 
geographical area, ranging from deprived to affluent neighbourhoods. There is scope, 
therefore to examine how formal referral pathways – through community pharmacies – can 
be used to improve the early detection of cancer. 
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